Lentinan is a polysaccharide isolated from the fruit body of shiitake mushroom (Lentinula edodes).
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Molar mass | ~ 500,000 Da |
  (what is this?) (verify) | |
Chemistry
editLentinan is a β-1,3 beta-glucan with β-1,6 branching. It has a molecular weight of 500,000 Da and specific rotation of +14-22° (NaOH).
Research
editPreclinical studies
editAn in vitro experiment showed lentinan stimulated production of white blood cells in the human cell line U937.[1] Lentinan is thought to be inactive in humans when given orally and is therefore administered intravenously. The authors of an in vivo study of lentinan suggested that the compound may be active when administered orally in mice.[2]
Human clinical trials
editLentinan has been the subject of a limited number of clinical studies in cancer patients in Japan;[3][4][5][6][7][8][9][10] however, evidence of efficacy is lacking.[11][12]
Adverse effects
editLentinan has been reported to cause shiitake mushroom dermatitis.[13]
See also
editReferences
edit- ^ Sia GM, Candlish JK (March 1999). "Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line". Phytotherapy Research. 13 (2): 133–137. doi:10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O. PMID 10190187.
- ^ Ng ML, Yap AT (October 2002). "Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes)". Journal of Alternative and Complementary Medicine. 8 (5): 581–589. doi:10.1089/107555302320825093. PMID 12470439.
- ^ Yang P, Liang M, Zhang Y, Shen B (August 2008). "Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC". Advances in Therapy. 25 (8): 787–794. doi:10.1007/s12325-008-0079-x. PMID 18670743. S2CID 33140754.
- ^ Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H, Yanaga K (June 2006). "[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]". Gan to Kagaku Ryoho. Cancer & Chemotherapy (in Japanese). 33 Suppl 1 (1): 106–109. PMID 16897983.
- ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepato-Gastroenterology. 46 (28): 2662–2668. PMID 10522061.
- ^ Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (July 2009). "Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer". Anticancer Research. 29 (7): 2739–2745. PMID 19596954.
- ^ Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, et al. (July 2009). "Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer". Anticancer Research. 29 (7): 2611–2617. PMID 19596936.
- ^ Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, et al. (2009). "Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life". Hepato-Gastroenterology. 56 (90): 547–550. PMID 19579640.
- ^ Isoda N, Eguchi Y, Nukaya H, Hosho K, Suga Y, Suga T, et al. (2009). "Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma". Hepato-Gastroenterology. 56 (90): 437–441. PMID 19579616.
- ^ Shimizu K, Watanabe S, Watanabe S, Matsuda K, Suga T, Nakazawa S, Shiratori K (2009). "Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer". Hepato-Gastroenterology. 56 (89): 240–244. PMID 19453066.
- ^ "Lentinan". WebMD. Retrieved June 10, 2017.
- ^ "Lentinan". Memorial Sloan Kettering Cancer Center. Retrieved June 10, 2017.
- ^ Nakamura T (August 1992). "Shiitake (Lentinus edodes) dermatitis". Contact Dermatitis. 27 (2): 65–70. doi:10.1111/j.1600-0536.1992.tb05211.x. PMID 1395630. S2CID 7320474.